LB082 - CLINICAL OUTCOMES AS A FUNCTION OF CHEMOTHERAPY AND NUTRITIONAL SUPPORT IN CANCER PATIENTS: C-REALITY STUDY

LB082

CLINICAL OUTCOMES AS A FUNCTION OF CHEMOTHERAPY AND NUTRITIONAL SUPPORT IN CANCER PATIENTS: C-REALITY STUDY

A. Alptekin Sarioglu^1,* on behalf of the C-REALITY Study Group

¹Abbott Nutrition, Abbott Laboratories, Istanbul, Türkiye

Rationale: To evaluate nutritional status, anthropometrics and muscle health outcomes, as a function of chemotherapy (CT) and oral nutritional supplements (ONS) utilization in cancer patients

Methods: A total of 139 patients with colon (n=53), lung (n=48) or gastric (n=38) cancer (mean±SD age 61.7±10.6 years; 69.1% male) were included in this 24-week non‑interventional observational study. Anthropometrics, handgrip strength (HGS), gait speed (6m walk), muscle loss and R‑MAPP tools (MUST and SARC‑F) were assessed at baseline and week 24 by ONS use and CT completion.

Results: ONS was recommended to 36.7% of patients. CT completion rate was 72.7%, irrespective of cancer type.Both ONS-treated (ONS+) and CT-complete (CT+) groups showed improved gait speed (0.78±0.22 vs. 0.86±0.23m/s, p=0.011 and 0.75± 0.19m/s vs. 0.85±0.22m/s, p<0.001, respectively) and maintained low-risk SARC-F status at week 24 (p=0.048 and p=0.007). Improvement from baseline PG-SGA stage B-C  (malnourished) to Stage A status at week 24 was more likely in ONS+ vs. ONS-naïve groups of CT+ patients (8.6% vs. 3.6%). MUST scores in CT+ were improved at week 24 (1.18±1.3 vs. 0.74±1.27, p=0.004). At baseline, ONS+ had worse weight (p=0.024), MUST (p=0.044), PG-SGA (p<0.001) and SARC-F scores (p=0.009). Gait speed (0.71 vs. 0.77±0.2 m/s, p=0.012) and HGS (27.6(13.3-39.2) vs. 28.4(13.9-44.1) kg, p=0.004) were significantly improved in ONS+/CT+ vs. ONS-/CT-.

Conclusion: Concomitant ONS use during CT appears to support functional recovery and muscle strength in cancer patients. Given the poorer baseline nutritional and muscle status in ONS treated patients, these findings highlight the importance of early screening and proactive nutritional intervention. Integrating such strategies within a prehabilitation framework may improve muscle health and enhance treatment tolerance in cancer patients.

Disclosure of Interest: A. Alptekin Sarioglu Other: Aysugul Alptekin Sarioglu, M.D. is an Abbott employee. Other authors declare that they have no conflict of interest